Literature DB >> 17933978

Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease.

Daniel El Fassi1, Ole Clemmensen, Claus H Nielsen, Rona Z Silkiss, Laszlo Hegedüs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17933978     DOI： 10.1210/jc.2007-1238

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  6 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 2.  Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Yasmin Shayesteh; Walter M Jay
Journal:  Neuroophthalmology       Date:  2015-06-17

3.  Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.

Authors:  G Vannucchi; I Campi; M Bonomi; D Covelli; D Dazzi; N Currò; S Simonetta; P Bonara; L Persani; C Guastella; J Wall; P Beck-Peccoz; M Salvi
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

4.  Distribution of lymphocyte subpopulations in thyroid glands of human autoimmune thyroid disease.

Authors:  Bingbing Zha; Xiuyan Huang; Jun Lin; Jun Liu; Yingyong Hou; Guilong Wu
Journal:  J Clin Lab Anal       Date:  2014-01-29       Impact factor: 2.352

5.  Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.

Authors:  Irene Campi; Guia Vannucchi; Ilaria Muller; Elisa Lazzaroni; Nicola Currò; Martina Dainese; Benedetta Montacchini; Danila Covelli; Claudio Guastella; Lorenzo Pignataro; Laura Fugazzola; Maura Arosio; Mario Salvi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-25       Impact factor: 5.555

Review 6.  New Therapeutic Horizons for Graves' Hyperthyroidism.

Authors:  Laura C Lane; Tim D Cheetham; Petros Perros; Simon H S Pearce
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.